Abstract:Objective: To establish and evaluate diagnostic efficacy and applicability of serum Golgi protein (GP) 73 based non-invasive diagnostic model with other conventional serological indicators for compensated stage hepatitis B cirrhosis. Methods: 666 cases with chronic hepatitis B (CHB) who had visited to the Fifth Medical Center of People's Liberation Army General Hospital from January 2010 to December 2017 were selected as the study subjects, and were classified according to compensated stage cirrhosis into clinical and pathological diagnosis group based on whether or not the liver histological examination was performed. A diagnostic model of compensated stage hepatitis B cirrhosis in the clinical diagnosis group was established. The current clinically used diagnostic model of liver cirrhosis, aspartate aminotransferase/platelet ratio index (APRI), fibrosis index (FIB)-4 and liver stiffness measurement (LSM) were compared. Eventually, the diagnostic model was verified step by step by pathological diagnosis group. Results: The area under the receiver operating characteristic curve (AUC) of GP73 and APRI, FIB-4, and LSM for cirrhosis patients in the clinical diagnosis group were 0.842, 0.857, 0.864, and 0.832, respectively. The diagnostic efficiency of the four indicators were of similar (P value > 0.05). A diagnostic model of compensated stage hepatitis B cirrhosis (GAPA) using logistic regression analysis was established: LogitP = 1/ [1 + exp (1.614-0.054 × GP73-0.045 × Age + 0.030 × PLT-0.015 × ALP)]. The AUC of the model was as high as 0.940 and the optimal cut-off value were 0.41. The corresponding diagnostic sensitivity and specificity were 0.92 and 0.82, respectively. The diagnostic efficiency was better than that of APRI, FIB-4, LSM and GP73 alone (P < 0.05). The AUC of GAPA was 0.877 in the pathological diagnosis group, which was similar to the diagnostic efficacy of LSM (0.891) and FIB-4 (0.847) (P > 0.1), but still superior to that of APRI (0.811) and GP73 alone (0.780) (P < 0.001). Conclusion: GAPA, a diagnostic model for compensated stage hepatitis B cirrhosis established in this study, has a good diagnostic efficacy in both the clinical and pathological diagnosis group, and has certain auxiliary diagnostic value in the areas where resources are relatively scarce or where LSM has not been developed.

A Time-Resolved Fluorescence Immunoassay of Golgi Protein 73 and Its Application in Hepatitis B Virus Related Liver Cirrhosis

Detection of Hepatitis B Virus Large Surface Protein Using a Time‐Resolved Immunofluorometric Assay

GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections.

Golgi Protein 73(GP73), a Useful Serum Marker in Liver Diseases

Serum GP73 Combined AST and GGT Reflects Moderate to Severe Liver Inflammation in Chronic Hepatitis B.

The Diagnostic Potential of Golgi Protein 73 for Cirrhosis in Patients with Chronic Hepatitis C

Serum Gp73, A Marker For Evaluating Progression In Patients With Chronic Hbv Infections

Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3

[Establishment and Preliminary Application of Serum Golgi Protein 73 Based Noninvasive Diagnostic Model for Compensated Stage Hepatitis B Cirrhosis].

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

[Detection and Evaluation of Serum GP73, a Resident Golgi Glycoprotein, As a Marker in Diagnosis of Hepatocellular Carcinoma].

Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B

Serum GP73 - An Additional Biochemical Marker for Liver Inflammation in Chronic HBV Infected Patients with Normal or Slightly Raised ALT

Establishment of Interleukin‐18 Time‐resolved Fluorescence Immunoassay and Its Preliminary Application in Liver Disease

Serum Gp73 is Also a Biomarker for Diagnosing Cirrhosis in Population with Chronic HBV Infection.

The Clinical Significance of Up-Converting Phosphor Immunochromatography in Detecting Hepatitis B Virus Large Envelope Protein in Various Types of Chronic Liver Disease

[Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].

[Diagnostic Application of Serum GP73 and the Relevant Mechanism in the Diagnosis of Liver Cirrhosis].

Serum GP73 for Diagnosing Decompensated Cirrhosis in Population with Chronic HBV Infections

Serum Golgi protein 73 as a tumor marker in diagnosis of primary hepatic cancer

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.